| |
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now.
|
|
Today’s Big NewsApr 25, 2024 |
| By Max Bayer Bristol Myers Squibb is cutting $1.5 billion in costs through 2025, including layoffs to more than 2,000 employees in 2024. The pharma says it will reinvest the capital into high-performing assets. |
|
|
|
By Angus Liu After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin. CEO Pascal Soriot argued the deals were made to build the company’s future. |
By Conor Hale “This is the most transformational product that I've seen in my career with the company,” CEO Mike Mahoney said on Boston Scientific’s first-quarter earnings call this week. |
By Andrea Park Neurocrine Biosciences’ newest educational campaign wants frustrated congenital adrenal hyperplasia patients to ask, “What the C@H?!” |
|
Tuesday, May 7, 2024 | 11 ET / 8 am PT This webinar dives into challenges and strategies in commercializing cell and gene therapies. Experts explore process standardization, treatment tracking tech, network channel strategy, and scaling for commercial success in this promising but complex field. Register now.
|
|
By Zoey Becker Facing pressure from the Inflation Reduction Act and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO Chris Boerner says the Beyenzi-maker had a "good start" with the first quarter. |
By Gabrielle Masson After BioMarin’s new leadership conducted a “strategic R&D asset review,” the company is prioritizing three of its “most productive” assets, leaving four candidates on the wayside. |
By Conor Hale Researchers at the University of Washington’s Institute for Protein Design have put forward a paper showing its AI algorithms can help create millions of never-before-seen drug-like peptides—a field that Big Pharmas have described as the next wave of drug discovery. |
By Nick Paul Taylor Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to grow its U.S. field force by 30% as it works with Eisai on direct to patient and caregiver omnichannel marketing campaigns. |
By Fraiser Kansteiner Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co. and Johnson & Johnson about the high costs of their drugs, Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.” |
By Annalee Armstrong Regeneron is signing another major deal in gene editing—and, this time, it’s Mammoth. Mammoth Biosciences, that is. The two companies will collaborate on in vivo CRISPR-based gene editing therapies in a deal worth $100 million upfront plus $370 million in milestones per target. |
By Fraiser Kansteiner Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. In fact, Sanofi is already gearing up for the antibody’s potential debut in what CEO Paul Hudson dubbed the drug’s “next major growth pillar.” |
By James Waldron Keen watchers of Deloitte’s annual reports on Big Pharma will have noticed a depressing trend—ever-increasing costs for developing drugs over the past decade as the return on investment sinks. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness. |
|
|---|
|
|
|
Wednesday, May 13, 2024 | 10 ET / 7 am PT This webinar unveils AI's transformative role in life sciences, presented by industry experts. Learn how AI process automation expedites drug development, ensures regulatory compliance, enhances communication, and boosts collaboration. Register now.
|
|
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBookUnlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
